Lv4
510 积分 2021-05-14 加入
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
22小时前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
3个月前
已完结
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
6个月前
已完结
Dictionary of Pharmaceutical Medicine
8个月前
已关闭
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
9个月前
已完结
AI science search engines are exploding in number — are they any good?
11个月前
已完结
皖公网安备34019202002308
